RTW

Allurion Closes $48 Million Convertible Senior Secured Note Financing with RTW Investments

Retrieved on: 
Wednesday, April 17, 2024
Biotechnology, Pharmaceutical, Managed Care, General Health, Health, Health Technology, Fitness & Nutrition, Other Health, Partnership, U.S. FDA, Growth, Obesity, Partner (business rank), RTW, Investment

Allurion Technologies, Inc. (NYSE: ALUR) (“Allurion” or the “Company”), a company dedicated to ending obesity, today announced the closing of a $48 million convertible senior secured note financing with certain entities managed by RTW Investments, LP (“RTW”).

Key Points: 
  • Allurion Technologies, Inc. (NYSE: ALUR) (“Allurion” or the “Company”), a company dedicated to ending obesity, today announced the closing of a $48 million convertible senior secured note financing with certain entities managed by RTW Investments, LP (“RTW”).
  • "RTW’s investment underscores our shared belief in the long-term potential of the Allurion Program,” said Dr. Shantanu Gaur, Founder and CEO of Allurion.
  • The investment furthers our long-term partnership with RTW and provides us additional flexibility to achieve our long-term goals,” Dr. Gaur continued.
  • “We are pleased to strengthen our relationship with Allurion as it continues its mission to end obesity around the world.

Artios Pharma Bolsters Board of Directors with Appointment of Chris Liu, PhD

Retrieved on: 
Tuesday, April 9, 2024
Biotechnology, Kite, Business, Business administration, Patient, Research, DNA, Fudan University, Acquisition, NYU, MBA, Doctor of Philosophy, DDR, Master of Business Administration, Therapy, Drug development, Investment, RTW

CAMBRIDGE, United Kingdom and NEW YORK, April 09, 2024 (GLOBE NEWSWIRE) -- Artios Pharma Limited (“Artios”), clinical-stage biotech company led by pioneers of DNA damage response (“DDR”) drug development, announces the appointment of Chris Liu, Ph.D., Senior Research Analyst specializing in oncology at RTW Investments, LP (“RTW”), to its Board of Directors.

Key Points: 
  • CAMBRIDGE, United Kingdom and NEW YORK, April 09, 2024 (GLOBE NEWSWIRE) -- Artios Pharma Limited (“Artios”), clinical-stage biotech company led by pioneers of DNA damage response (“DDR”) drug development, announces the appointment of Chris Liu, Ph.D., Senior Research Analyst specializing in oncology at RTW Investments, LP (“RTW”), to its Board of Directors.
  • Niall Martin, Chief Executive Officer of Artios, said: “We are delighted to welcome Chris, a prominent research analyst to our Board of Directors.
  • Chris Liu, Ph.D. Board Director of Artios, added: “RTW is now a top shareholder of Artios following the acquisition of Arix and the expansion of our equity interest, which reflects both our confidence and excitement in Artios’ innovative platform targeting broad aspects of the DNA damage response.
  • He currently serves on the board of NiKang Therapeutics, Oricell Therapeutics and Nuance Pharma as a Board Director or Observer.

ARCA biopharma and Oruka Therapeutics Announce Merger Agreement

Retrieved on: 
Wednesday, April 3, 2024
Paragon, Freedom, Psoriasis, Biotechnology, ARCA, Disease, Patient, Paradigm, Psoriatic arthritis, Standard of care, Doctor of Philosophy, Investment, RTW, Engineering, Pharmaceutical industry

WESTMINSTER, Colo. and WALTHAM, Mass., April 03, 2024 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (NASDAQ: ABIO) (“ARCA”), and Oruka Therapeutics (“Oruka”), a privately held biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases, including plaque psoriasis, announced today that they have entered into a definitive agreement to combine the companies in an all-stock transaction. The resulting entity will focus on advancing Oruka’s pipeline of potentially best-in-class biologics, including ORKA-001 (an IL-23p19 inhibitor) and ORKA-002 (an IL-17A/F inhibitor). Upon completion of the merger, the combined company plans to operate under the name Oruka Therapeutics, Inc. and trade on Nasdaq under the ticker symbol “ORKA”.

Key Points: 
  • Upon completion of the merger, the combined company plans to operate under the name Oruka Therapeutics, Inc. and trade on Nasdaq under the ticker symbol “ORKA”.
  • In addition, prior to closing of the merger, ARCA expects to declare a cash dividend to the pre-merger ARCA stockholders equal to the amount by which ARCA’s net cash exceeds $5 million.
  • “Our mission at Oruka is to offer people affected with chronic skin diseases the most possible freedom from their condition.
  • Oruka is the third company founded based on assets generated by Paragon Therapeutics (“Paragon”).

ARCA biopharma and Oruka Therapeutics Announce Merger Agreement

Retrieved on: 
Wednesday, April 3, 2024
Paragon, Freedom, Psoriasis, Biotechnology, ARCA, Disease, Patient, Paradigm, Psoriatic arthritis, Standard of care, Doctor of Philosophy, Investment, RTW, Engineering, Pharmaceutical industry

WESTMINSTER, Colo. and WALTHAM, Mass., April 03, 2024 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (NASDAQ: ABIO) (“ARCA”), and Oruka Therapeutics (“Oruka”), a privately held biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases, including plaque psoriasis, announced today that they have entered into a definitive agreement to combine the companies in an all-stock transaction. The resulting entity will focus on advancing Oruka’s pipeline of potentially best-in-class biologics, including ORKA-001 (an IL-23p19 inhibitor) and ORKA-002 (an IL-17A/F inhibitor). Upon completion of the merger, the combined company plans to operate under the name Oruka Therapeutics, Inc. and trade on Nasdaq under the ticker symbol “ORKA”.

Key Points: 
  • Upon completion of the merger, the combined company plans to operate under the name Oruka Therapeutics, Inc. and trade on Nasdaq under the ticker symbol “ORKA”.
  • In addition, prior to closing of the merger, ARCA expects to declare a cash dividend to the pre-merger ARCA stockholders equal to the amount by which ARCA’s net cash exceeds $5 million.
  • “Our mission at Oruka is to offer people affected with chronic skin diseases the most possible freedom from their condition.
  • Oruka is the third company founded based on assets generated by Paragon Therapeutics (“Paragon”).

Mirador Therapeutics Launches to Accelerate the Next Generation of Precision Medicines for Immune-mediated Diseases

Retrieved on: 
Thursday, March 21, 2024
Health, Infectious Diseases, Genetics, Other Health, General Health, Pharmaceutical, Biotechnology, Farallon Capital, ARCH Venture Partners, Patient, Merck, Medicine, Investment, Therapy, OrbiMed, Machine learning, Probability, RTW, Pharmaceutical industry

Mirador has raised more than $400 million in financing led by ARCH Venture Partners, with early investments from OrbiMed and Fairmount.

Key Points: 
  • Mirador has raised more than $400 million in financing led by ARCH Venture Partners, with early investments from OrbiMed and Fairmount.
  • “At Mirador, we envision a bold new era of precision medicine for immune-mediated inflammatory and fibrotic diseases driven by speed and superior development accuracy,” said Mark C. McKenna, chairman and CEO of Mirador.
  • To accelerate development, Mirador utilizes Mirador360, its proprietary precision development engine that leverages recent breakthroughs in human genetics and cutting-edge data science.
  • Mirador360 also allows Mirador to develop diagnostics and stratify heterogeneous patient populations for precise clinical development.

UroGen Pharma Delivers Double Digit JELMYTO® Growth and Prepares for the Next Phase of the Company with on Track Rolling Submission of UGN-102

Retrieved on: 
Thursday, March 14, 2024
Oncology, Health, FDA, Clinical Trials, Pharmaceutical, Biotechnology, Research, Biopsy, Conference, Carcinoma, Chemistry, Webcast, New Drug Application, Medac, Patient, Mitomycins, NDA, CMC, Software, Safety, Nephrectomy, Patent, Medicare, Investment, RTW, ATLAS, Ureteroscopy, Gesellschaft mit beschränkter Haftung, Food, Pharmaceutical industry

The first part of the submission was the Chemistry, Manufacturing and Controls (CMC) sections.

Key Points: 
  • The first part of the submission was the Chemistry, Manufacturing and Controls (CMC) sections.
  • The FDA indicated that evaluation of duration of complete response at 12-months from the pivotal ENVISION trial will be sufficient to support submission of the NDA.
  • The company plans to complete the submission in September 2024 with a potential FDA decision as early as the first quarter of 2025.
  • Generated annual net product revenue of $82.7 million in 2023, compared with $64.4 million in 2022 in representing ~28% annual growth.

Latest Updates of Viva Biotech's Portfolio Companies

Retrieved on: 
Wednesday, March 6, 2024
Fabry disease, RMB, PD, Drug development, Strong, Ohio State University, RNA, Insight Partners, Pharmacology, American College, Radiopharmaceutical, VBI, Willebrand, RTW, Pattern hair loss, GMP, Stroke, Good manufacturing practice, Therapy, Skin, GCS, Atopic dermatitis, Safety, Pharmacokinetics, Von Willebrand factor, Investment, AstraZeneca, Innovation, Groundbreaking, Patient, ARCH Venture Partners, Pharmaceutical industry

NEWARK, Calif.-- AceLink Therapeutics, Inc., invested and incubated by Viva BioInnovator (VBI), is a clinical-stage biopharmaceutical company developing next generation oral substrate reduction therapies (SRTs). Recently they announced that the findings from their Phase 1 study of AL01211 in healthy volunteers have been published in the peer-reviewed journal Clinical Pharmacology in Drug Development, a journal of the American College of Clinical Pharmacy. AL01211 is a potent, oral, glucosylceramide synthase (GCS) inhibitor being developed for the treatment of Fabry disease and Type 1 Gaucher disease.

Key Points: 
  • This continuous innovation keeps companies up to date and promotes the evolution of R&D and the success of commercialization.
  • Recently, Viva Biotech's portfolio companies have new updates.
  • NEWARK, Calif.-- AceLink Therapeutics, Inc., invested and incubated by Viva BioInnovator (VBI), is a clinical-stage biopharmaceutical company developing next generation oral substrate reduction therapies (SRTs).
  • Previously, the company had completed a $5.4 million seed funding round, with investors including Rev1 Ventures, Broadview Ventures, and Viva Biotech.

RTW Charitable Foundation Announces Six Research Grant Recipients

Retrieved on: 
Monday, February 12, 2024
Biotechnology, Health, Philanthropy, Pharmaceutical, Neurology, Research, Fund Raising, Genetics, Foundation, Science, Clinical Trials, Therapy, RTW, University College London, Grant (money), Metabolism, Toxicity, Doctor of Philosophy, IRF2BPL, Nationwide, University, Gene, Nonprofit organization, Growth, Hospital, Life, Weakness, Translation, University of California, Patient, NIHR, Child, AAV, Kidney transplantation, Kidney failure, Pharmaceutical industry

RTW Charitable Foundation (“RTWCF”) announced today that it has awarded $900,000 in research grants to support six research studies.

Key Points: 
  • RTW Charitable Foundation (“RTWCF”) announced today that it has awarded $900,000 in research grants to support six research studies.
  • “Optimizing AAV-SPL gene therapy for sphingosine phosphate lyase insufficiency syndrome” (Julie Saba, University of California, San Francisco, San Francisco, CA).
  • “RTW Charitable Foundation is proud to provide financial and scientific support to these six incredible researchers and their respective studies.
  • In addition to delivering financial resources, RTWCF also provides grant recipients with hands-on scientific support, helping them improve or further develop their research and research tools and identify new therapeutic targets.

Scheme Effective

Retrieved on: 
Monday, February 12, 2024
RTW, Letter, Regulation, Financial services, Person, Sale, Prejudice, Regulation D, Risk, International (Amtrak train), Jefferies

This announcement is not for publication or distribution, directly or indirectly, in or into the United States of America.

Key Points: 
  • This announcement is not for publication or distribution, directly or indirectly, in or into the United States of America.
  • This announcement is not an offer of securities for sale into the United States.
  • The Consideration Shares will be offered and sold for investment purposes only in the United States or to U.S.
  • RTW Bio reserves the right to refuse to accept any subscriptions, resales or other transfers of Consideration Shares to U.S.

Suspension of Trading in Shares

Retrieved on: 
Monday, February 12, 2024
RTW, Letter, Regulation, Financial services, Person, Sale, Prejudice, Regulation D, Risk, International (Amtrak train), Jefferies

The Consideration Shares will be offered and sold for investment purposes only in the United States or to U.S.

Key Points: 
  • The Consideration Shares will be offered and sold for investment purposes only in the United States or to U.S.
  • Consideration Shares will be offered and sold outside of the United States to investors that are not U.S.
  • The transferability of the Consideration Shares will be further restricted by the terms of the AI/QP Investor Letter, and any re-offer or resale of any Consideration Shares in the United States or to U.S.
  • RTW Bio reserves the right to refuse to accept any subscriptions, resales or other transfers of Consideration Shares to U.S.